BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31495737)

  • 1. [Treatment of oligometastatic or oligoprogression cancer].
    Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
    Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stereotaxic ablative radiotherapy in stage 1 non-small-cell lung cancer: Results of the phase 3 randomized trial "CHISEL"].
    Gerard M; Lerouge D; Le Guevelou J; Thariat J
    Bull Cancer; 2020 Feb; 107(2):145-147. PubMed ID: 32035650
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of primary disease (breast, non-small cell lung and prostate cancers) with irradiation in case of de novo metastatic cancer].
    Latorzeff I; Bourgier C; Pinel B; Hennequin C; Jimenez G; Chapet O; Zasadny X
    Cancer Radiother; 2019 Oct; 23(6-7):486-495. PubMed ID: 31501025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E
    Christ SM; Alongi F; Ricardi U; Scorsetti M; Livi L; Balermpas P; Lievens Y; Braam P; Jereczek-Fossa BA; Stellamans K; Ratosa I; Widder J; Peulen H; Dirix P; Bral S; Ramella S; Hemmatazad H; Khanfir K; Geets X; Jeene P; Zilli T; Fournier B; Ivaldi GB; Clementel E; Fortpied C; Oppong FB; Ost P; Guckenberger M
    Radiother Oncol; 2024 Jun; 195():110235. PubMed ID: 38508239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
    Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
    Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
    Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
    Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
    Niazi T; Elakshar S; Stroian G
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stereotactic body radiation radiotherapy for oligometastatic non-small cell lung cancer (NSCLC): A case report].
    Leduc C; Antoni D; Quoix É; Noël G
    Cancer Radiother; 2015 May; 19(3):192-7. PubMed ID: 25841992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
    Rusthoven CG; Yeh N; Gaspar LE
    Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current uses and applications of stereotactic body radiation therapy.
    Ramos-Prudencio R; Lozano-Ruiz F; Rodríguez-Laguna A; Poitevin-Chacón MA
    Gac Med Mex; 2023; 159(3):262-269. PubMed ID: 37494714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation therapy for oligometastatic non-small cell lung cancer.
    Salama JK; Schild SE
    Cancer Metastasis Rev; 2015 Jun; 34(2):183-93. PubMed ID: 25948377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy (SBRT) for Stage I lung cancer.
    Nagata Y; Kimura T
    Jpn J Clin Oncol; 2018 May; 48(5):405-409. PubMed ID: 29635536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
    Bansal P; Rusthoven C; Boumber Y; Gan GN
    Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy for metastases to the kidney in patients with non-small cell lung cancer: a new treatment paradigm for durable palliation.
    Verma V; Simone CB
    Ann Palliat Med; 2017 Apr; 6(2):96-103. PubMed ID: 28480719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
    Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
    Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.